Literature Selection / Selezione della Letteratura

• Huang EH et al.: "Locoregional treatment outcomes for breast cancer patients with ipsilateral supraclavicular metastases at diagnosis", Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):490-6
• Toledano A et al.: "Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: final results of the ARCOSEIN trial", J Clin Oncol. 2007 Feb 1;25(4):405-10
• Catania C et al.: "Fulvestrant in heavily pre-treated patients with advanced breast cancer: results from a single compassionate use programme centre", Breast Cancer Res Treat. 2007 Jan 27
• Paganelli G et al.: "IART((R)): Intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation", Breast. 2007 Feb; 16(1): 17-26
• Tercyak KP et al.: "Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing", J Clin Oncol. 2007 Jan 20;25(3):285-91
• Barron TI et al.: "Early discontinuation of tamoxifen: a Lesson for oncologists", Cancer. 2007 Jan 22; [Epub ahead of print]
• Intra M et al.: "Sentinel lymph node biopsy is feasible even after total mastectomy", J Surg Oncol. 2007 Jan 29;95(2):175-179 [Epub ahead of print]
• Boyd NF et al.: "Mammographic Density and the Risk and Detection of Breast Cancer", N Engl J Med. 2007 Jan 18;356(3):227-236
• Dowsett M et al.: "Prognostic Value of Ki67 Expression After Short-Term Presurgical Endocrine Therapy for Primary Breast Cancer", J Natl Cancer Inst 2007; 99: 167-170
• Geiger AM et al.: "Recurrences and second primary breast cancers in older women with initial early-stage disease", Cancer. 2007 Jan 22; [Epub ahead of print]
• Roychouduri R et al.: "Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study", BMC Cancer. 2007 Jan 15;7(1):9
• Liu R et al.: "The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells", N Engl J Med. 2007 Jan 18;356(3):217-226
• Cade JE et al.: "Dietary fibre and risk of breast cancer in the UK Women's Cohort Study", Int J Epidemiol. 2007 Jan 24; [Epub ahead of print]

Editorial / Editoriale

• "Men diagnosed with breast cancer have a higher risk of suffering a second cancer" - Sacha Satram-Hoang, Epidemiology Division, School of Medicine, University of California, Irvine, CA, USA

"Our retrospective cohort study found that men diagnosed with breast cancer have a 16% higher risk of suffering a second cancer (not a spread of the original tumor) than the general male population. Data analyzed from the California Cancer Registry during the period 1988-2003 included 1,926 men aged 85 or younger diagnosed with a first primary breast cancer. These men are especially prone to developing a second primary breast, stomach and melanoma skin cancer. One possible explanation for the association between the first and second cancer include genetic mutations in the BRCA1 and BRCA2 genes. Male tumors related to BRCA1 and BRCA2 include breast, melanoma, stomach, prostate, colon and pancreatic cancer. Further, the particularly high risk for bilateral breast disease and the high risk among early onset cases are an indicator of a hereditary cancer syndrome. Other possible explanations for the associations include shared hormonal abnormalities, and shared lifestyle and environmental risk factors between the first and second cancer. Studying the occurrence of second primary cancers holds important implications for cancer etiology and preventive medicine. These results will have substantial medical implications for cancer patients as well as for relatives that are at risk of the disease. Medical interventions to address increased risk of second cancer include increased surveillance, chemoprevention, and prophylactic surgery." (Comment on paper: Satram-Hoang S et al.:"Risk of Second Primary Cancer in Men with Breast Cancer", Breast Cancer Res. 2007 Jan 25;9(1):R10)

Calendar of Events / Prossimi Eventi Senologici

• The 12th Annual Multidisciplinary Symposium on Breast Disease, February 15 – 18, 2007, The Ritz-Carlton Amelia Island, Florida
• 24th Annual Miami Breast Cancer Conference, Feb 21 - 24, 2007,  Miami Beach, FL, USA
• 4th Annual Orlando Breast Cancer Conference", Mar 31 - Apr 1, 2007, Orlando, FL, USA

Literature Selection / Selezione della Letteratura

• Fransman W et al.: "Nurses with dermal exposure to antineoplastic drugs: reproductive outcomes", Epidemiology. 2007 Jan;18(1):112-9
• Mok T et al.: "A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity", Ann Oncol. 2007 Jan 17; [Epub ahead of print]
• Losina E et al.: "Visual screening for malignant melanoma: a cost-effectiveness analysis", Arch Dermatol. 2007 Jan;143(1):21-8
• Oettle H et al.: "Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer", JAMA. 2007 Jan 17;297:267-277
• Villanueva CM et al.: "Bladder Cancer and Exposure to Water Disinfection By-Products through Ingestion, Bathing, Showering, and Swimming in Pools", Am J Epidemiol. 2007 Jan 15;165(2):148-56
• Lane BR et al.: "5-Year outcomes of laparoscopic partial nephrectomy", J Urol. 2007 Jan;177(1):70-4
• Kraev A et al.: "Wedge resection vs lobectomy: 10-year survival in stage I primary lung cancer", Chest. 2007 Jan;131(1):136-40
• Chan JK et al.: "Association of lymphadenectomy and survival in stage I ovarian cancer patients", Obstet Gynecol. 2007 Jan;109(1):12-9
• Willett EV et al.: "Does smoking or alcohol modify the risk of Epstein-Barr virus-positive or -negative Hodgkin lymphoma?", Epidemiology. 2007 Jan;18(1):130-6
• Tedeschi R et al.: "Activation of maternal Epstein-Barr virus infection and risk of acute leukemia in the offspring", Am J Epidemiol. 2007 Jan 15;165(2):134-7

Editorial / Editoriale

• "Efficacy of octreotide in patients with advanced multifocal hepatocellular carcinoma" - Hubert Blum, Department of Medicine II, University Hospital Freiburg, Freiburg, Germany

 "Hepatocellular carcinoma (HCC) is a malignant liver tumor that arises from hepatocytes and has a generally very poor prognosis with a 5-year survival rate of <5% in symptomatic patients. Therapeutic options for HCCs fall into 5 categories: surgical interventions (tumor resection and liver transplantation, LTx), percutaneous interventions (e.g., ethanol or acetic acid injection, radiofrequency thermal ablation), transarterial interventions (embolization, chemoperfusion or chemoembolization), radiation and drugs. A number of systemic chemotherapies, hormonal and other drugs have been evaluated in clinical trials. While most chemotherapeutic agents, tamoxifen and interferon-alpha have not been shown to be effective in randomized controlled clinical trials, based on previous reports a number of substances deserve further clinical evaluation in qualified clinical trials, e.g., gemcitabine, thymostimulin, pravastatin, thalidomide and megestrol acetate as well as several antiangiogenic small molecules, e.g., erlotinib, sorafenib, gefitinib, as well as antiangiogenic monoclonal antibodies, e.g., bevacizumab or cetuximab, Cox-2 inhibitors in combination with capecitabine, pamidronate and others. Based on promising data from a previous study (Kouroumalis A etal.Gut 1998; 42: 42-447), we explored the therapeutic efficacy of octreotide in a mulicenter, randomized, placebo-controlled trial including 120 patients with advanced multifocal HCC. The study revealed that octreotide alone is ineffective at this stage of the disease and should, therefore, not be given. Possibly, octreotide may be efficacious at an earlier stage of the disease and/ or in combination with other therapeutic strategies" (Comment on paper: Becker G, Allgaier HP, Olschewski M, Zähringer A and Blum HE; "Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study", Hepatology. 2007 Jan;45(1):9-15. Hepatology 2007;45:9-15)

Clinical Guidelines / Linee Guida Cliniche (link)

• "American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors" - CA Cancer J Clin 2007; 57:7-28
• "Cryotherapy for renal cancers" - NICE - National Institute For Clinical Excellence, London, UK
• "Laparoscopic distal pancreatectomy: guidance" - NICE - National Institute For Clinical Excellence, London, UK

Press Releases / Comunicati Stampa

• "Tarceva : European approval for pancreatic cancer treatment" - Roche
• "New drug therapy to combat graft-vs.-host disease in stem-cell patients shows significant reduction in deaths"  - Fred Hutchinson Cancer Research Center, Seattle, WA, USA
• "Arsenic Compound Improves Survival of Adults with Uncommon Form of Leukemia" - National Institutes of Health (NIH), U. S. Department of Health and Human Services
• "Aspirin Saves Lives of Cancer Patients Suffering Heart Attacks, Despite Fears of Bleeding" - The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA
• "Dual Gene Therapy Suppresses Lung Cancer in Preclinical Test" - The University of Texas, M. D. Anderson Cancer Center, Houston, TX, USA

Literature Selection / Selezione della Letteratura

• Baird DD et al.: "Association of physical activity with development of uterine leiomyoma", Am J Epidemiol. 2007 Jan 15;165(2):157-63 - Un regolare esercizio fisico può prevenire nelle donne lo sviluppo di fibromiomi uterini
• Edwards RD et al.: "Uterine-artery embolization versus surgery for symptomatic uterine fibroids", N Engl J Med. 2007 Jan 25;356(4):360-70 - In pazienti affette da fibromiomi dell'utero, l'embolizzazione arteriosa uterina consente, rispetto all'intervento chirurgico tradizionale, una ospedalizzazione più breve ed una più precoce ripresa dell'attività lavorativa, ma è associata ad una maggiore incidenza di complicanze e di reinterventi 
• Lockman S et al.: "Response to antiretroviral therapy after a single, peripartum dose of nevirapine", N Engl J Med. 2007 Jan 11;356(2):135-47 - Le donne affette da infezione da HIV rispondono meglio ad un regime farmacologico contenente nevirapina quando il trattamento viene avviato almeno sei mesi dopo una singola somministrazione del farmaco, praticata durante il parto al fine di prevenire l'infezione virale perinatale